BluePath SolutionsBluePath Solutions
Search
  • Home
  • About
  • Solutions
    • Our approach
    • Value Marketing & Communications
    • Modeling & Data Visualization
    • Health Economics & Outcomes Research
  • The Compass
  • Careers
  • Contact us
  • Home
  • A Snapshot of the Conclusions on Long-term Value of Healthcare Treatments Conducted by the Institute for Clinical and Economic Review Group
  • Blog

Blog

15MayMay 15, 2018

A Snapshot of the Conclusions on Long-term Value of Healthcare Treatments Conducted by the Institute for Clinical and Economic Review Group

Otis2021-10-15T11:29:34+00:00

The Institute for Clinical and Economic Review, a non-profit institute evaluates the cost-effectiveness of drugs, medical devices, medical procedures, and diagnostics. The Institute for Clinical and Economic Review has published...

By OtisBlog, Featured0 Comments
Read more...
01NovNovember 1, 2017

US Market Access – Key Considerations in a Changing Environment

Otis2021-10-15T11:30:13+00:00

Many life science manufacturers employ a payer size and control strategy in the US market. While this continues to be viable model, changes in formulary and benefit design result in...

By OtisBlog, Featured0 Comments
Read more...
02OctOctober 2, 2017

Emerging Barriers to Launch Access – the Impact of New Drug Coverage Policies

Otis2021-10-14T05:37:09+00:00

New drug coverage policies provide guidance around a payer’s coverage of new drugs in the time period between FDA approval and P&T committee review. As these policies proliferate, manufacturers may...

By OtisBlog, Featured0 Comments
Read more...
  Prev123

Recent Posts

01AprApril 1, 2025

Net Price Competition in the Ocular VEG-F Drug Market

This is the second in a series of posts in which BluePath will examine biopharmaceutical... read more

01MarMarch 1, 2025

US Physician-Administered Drug Market Overview

This is the first in a series of posts in which BluePath will explore biopharmaceutical... read more

24JanJanuary 24, 2025

CMS Update on Drugs Selected for Medicare Part D Price Negotiation

The Centers for Medicare and Medicaid Services (CMS) recently announced the next 15 brand drugs... read more

30OctOctober 30, 2024

Medicare Part B Drug Trends and Payment Dynamics 

In 2021, Medicare spending for Part B drugs was $43 billion and Part B drug... read more

20SepSeptember 20, 2024

FDA Proposes a Change in Biosimilar Switching Study Requirements 

The US Food and Drug Administration (FDA) has proposed that manufacturers of biosimilar drugs seeking... read more

  • Home
  • About
  • Solutions
  • The Compass
  • Careers

Contact us

1640 S Sepulveda Blvd, Suite 207
Los Angeles, CA 90025
United States

855.378.4115
310.774.0406

Follow BPS

Linkedin
veeva logo
hippa logo

©2021 BluePath Solutions, All Rights Reserved

  • Privacy Policy
  • Terms
BluePath Solutions © Copyright 2021. All Rights Reserved.
  • Home
  • About
  • Solutions
    • Our approach
    • Value Marketing & Communications
    • Modeling & Data Visualization
    • Health Economics & Outcomes Research
  • The Compass
  • Careers
  • Contact us